All In Biotech

Drug Trial Radar · NCT00067938

Bipolar Study in Adults at Least 18 Years of Age

Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.

Last checked: Nov 19, 2026Latest source record: Sep 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,200

Actual

Start

Aug 2003

Primary completion

Aug 2004

Study completion Aug 2004

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 5, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar study of tolerability, clinical response and patient satisfaction

Conditions

  • Bipolar Disorder

Interventions

  • lamotrigineDrug

    Lamotrigine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint will be the rate of rash during 12 weeks.Time frame: 12 Weeks

Locations

308 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Albertville, Alabama

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Fairhope, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Rogers, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fort Smith, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    North Little Rock, Arkansas

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Burbank, California

  • GSK Investigational Site

    Campbell, California

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    El Centro, California

  • GSK Investigational Site

    Fairfield, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Laguna Hills, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Oceanside, California

  • GSK Investigational Site

    Petaluma, California

  • GSK Investigational Site

    Poway, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Santa Barbara, California

Showing 40 of 308 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.